Plasma level of soluble receptor for advanced glycation end-products and aquaporin 5 in preterm infants with acute respiratory distress syndrome.

BACKGROUND: The aim of this study was to determine the plasma level of soluble receptors for advanced glycation end-products (sRAGE) and aquaporin 5 (AQP5) in preterm infants with acute respiratory distress syndrome (RDS). METHODS: Forty-three preterm infants diagnosed with RDS were the experimental group. Ten apparently healthy preterm neonate infants were as normal controls. The experimental group was further divided into three subgroups based on PaO2/FiO2 (P/F): the mild group (200

Urine AQP5 is a potential novel biomarker of diabetic nephropathy.

AIMS: To investigate if urinary AQP5 serves as a new potential biomarker of diabetic nephropathy. METHODS: Using an AQP5-specific enzyme-linked immunosorbent assay, we measured serum and urine AQP5 first in a cohort consisting of normal controls (n=26) and patients with diabetes mellitus (n=25) or diabetic nephropathy (n=33) and then in a validation cohort possessing normal controls (n=10), patients with diabetes mellitus (n=10) or diabetic nephropathy (n=14), and patients with chronic kidney disease of unknown etiology (n=10). We used various statistical methods including Pearson's correlation coefficient, ANOVA with Holm-Sidak test, Receiver Operator Curve, and multiple logistic regression to analyze the data. RESULTS: Urine AQP5/creatinine 1) is significantly higher in diabetic nephropathy than in other two groups, and in diabetic nephropathy stage V than in stage III; 2) correlates with serum creatinine, urine albumin, and multiple other known risk factors of the disease; and 3) improves the clinical models in distinguishing diabetic nephropathy from normal controls and diabetic mellitus. CONCLUSION: Our data suggest that urine AQP5/creatinine may possess diagnostic and prognostic values as a biomarker of diabetic nephropathy.